TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06651099

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mhealth application
Description: Individuals enrolled in the mhealth intervention will receive tailored content will include exercises focused on mobility, flexibility, core stabilization, and strengthening. Additionally, the mobile application will provide educational material on pain and health, covering topics such as the neurophysiology of pain, the multidimensional nature of low back pain, myths and facts about the condition, the importance of sleep, and stress management, which will include relaxation techniques and mindfulness. All content will be evidence-based, using clinical guidelines, systematic reviews and other high-quality studies to support inclusion in the mobile application. The intervention will be supervised by a physiotherapist, remotely via messaging or telephone calls.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise therapy
Description: Participants in this intervention will receive a printed booklet containing a description and recommendations for carrying out an exercise program at home, which will be characterized by general exercises (such as strengthening, mobilization). The intervention will be supervised by a physiotherapist, remotely via messaging or telephone calls.
Study: NCT06273124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SteadiSet Extended Wear Infusion Set
Description: Each participant will be given 12 Extended Wear Infusion Sets to wear over 12 wear periods up to 168 hours each.
Study: NCT06601894

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelets count
Description: the study include will take medical investigation data for all sickle cell patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelets count
Description: the study include will take medical investigation data for all sickle cell patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelets count
Description: the study include will take medical investigation data for all sickle cell patients.
Study: NCT06589726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a single oral dose of placebo matched to enpatoran in either of treatment period 1, 2, 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a single oral dose of placebo matched to enpatoran in either of treatment period 1, 2, 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a single oral dose of placebo matched to enpatoran in either of treatment period 1, 2, 3 and 4.
Study: NCT06341283

Intervention type: DRUG
Intervention: Abemaciclib and Letrozole/Anastrozole
Description: Take the treatment with Abemaciclib and Letrozole/Anastrozole at the same time.

Intervention type: DRUG
Intervention: Letrozole or Anastrozole
Description: Take the treatment with Letrozole or Anastrozole.

Intervention type: DRUG
Intervention: Abemaciclib and Fulvestrant
Description: Take the treatment with Abemaciclib and Fulvestrant at the same time.

Intervention type: DRUG
Intervention: Fulvestrant
Description: Take the treatment with Fulvestrant only.
Study: NCT06494956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant device
Description: A subcutaneous tunnel was established under general anesthesia, the electrode was connected to the stimulator, and the pulse generator was implanted in the skull.
Study: NCT06174701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy (PST)
Description: PST intervention in the form of one-on-one coaching in preparation for surgery and post-operative care. This coaching consists of educating and guiding the patient in developing problem-solving skills. Please refer to the PST Handbook for further detail on the therapy sessions.
Study: NCT04794998

Intervention type: DRUG
Intervention: Recommended treatment schedule
Description: Relatively selective Cox-2 inhibitors, Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin), Gentle Oxygen therapy

Intervention type: DRUG
Intervention: Control treatment schedule
Description: Treatment regimens different from the recommended one according to family phisicians personal practice.
Study: NCT05594199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Smoking Cessation Program
Description: This program consists of an e-learning smoking cessation education module and a tailored email messaging program.~The e-learning module addresses the potential health benefits to quitting smoking regarding surgery or recovering from a fracture. In addition, it provides information on getting support through the process of quitting smoking based on the individual's level of smoking dependence.~Email frequency and content will vary based on the participant's score and level of motivation. Information will include the risks associated with smoking before surgery or how quitting smoking can improve recovery from a fracture injury. Additional information includes the benefits of quitting smoking and developing coping strategies during a quit attempt. Motivational emails and references to free resources for additional smoking cessation support will also be provided.
Study: NCT06091033

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented rice
Description: 1,000 mg of black rice (Oryza Sativa L.) extract fermented with Lactobacillus for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1,000 mg of a placebo for 8 weeks
Study: NCT06403722

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard of care
Description: No intervention. Clinical evolution was recorded, looking for perinatal complications.

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard of care
Description: No intervention. Clinical evolution was recorded, looking for perinatal complications.

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard of care
Description: No intervention. Clinical evolution was recorded, looking for perinatal complications.

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard of care
Description: No intervention. Clinical evolution was recorded, looking for perinatal complications.
Study: NCT05427916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avance Solo
Description: Avance® Solo will include the collective description for a complete device capable of delivering negative pressure to the incision site and managing exudate generated by the incision.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optifoam
Description: Optifoam is a silicone backed foam that is conformable, with a border that is waterproof, flexible and breathable for increased comfort, with a wear time of up to seven days. It is a standard of care product that is given to patients for surgical wounds.
Study: NCT05415787

Intervention type: OTHER
Intervention: Blood sample
Description: 2 tubes Cell free DNA are taken during a blood sample already planned in the patient's care.

Intervention type: OTHER
Intervention: Urine sample
Description: Urine sample is taken during the consultation carried out for the patient's care
Study: NCT04386889

Intervention type: OTHER
Group type: OTHER
Intervention: Vasculitis In SLE
Description: 20 SLE female Egyptian patients, among them we are going to study the vasculitic pattern incidence.
Study: NCT05983393

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Erector spinae plane block was performed

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Erector spinae plane block was not applied.
Study: NCT03877822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habitual activity
Description: Two days of habitual physical activity, under normal free-living conditions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bed rest
Description: Two days of bed rest, to induce whole-body physical inactivity
Study: NCT06576739

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Spinal Manipulation
Description: Daily administration of combination of vitamin B6,,vitamin B12, and folic acid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: Daily administration of combination of vitamin B6,,vitamin B12, and folic acid
Study: NCT06364930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin 10mg Tab QD for 60 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 10mg Tab
Description: Placebo 10mg Tab QD for 60 months.
Study: NCT06577220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Recall
Description: Participants receive a scripted telephone recall from a trained patient navigator.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Recall
Description: Participants receive a scripted telephone recall from a trained patient navigator.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Recall
Description: Participants receive a scripted telephone recall from a trained patient navigator.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mailed HPV Self-Sampling Kit
Description: Participants receive a mailed kit that allows them to self-collect a cervical sample in their home and return it to a laboratory for human papillomavirus (HPV) testing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mailed HPV Self-Sampling Kit
Description: Participants receive a mailed kit that allows them to self-collect a cervical sample in their home and return it to a laboratory for human papillomavirus (HPV) testing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Participant receives telephone call from patient navigator within 3-5 days of receipt of self-collection kit. Patient navigator provides one-on-one education on cervical cancer screening and self-collection of cervical sample.
Study: NCT05356013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caplyta
Description: Atypical antipsychotic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill that contains no medicine.
Study: NCT06478251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NW-301V
Description: TCR-T T cell targeting KRAS G12V mutation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NW-301D
Description: TCR-T T cell targeting KRAS G12D mutation
Study: NCT05581849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Nightly Fasting
Description: Participants will engage in 14+ hours a night of fasting and no calorie containing food or beverages for 8 weeks. Participants will be allotted one cheat day per week, during which they will not need to fast (or track their times)- the day may change weekly and will be based on participant preference. Study staff and study participants will engage in a weekly coaching call (via phone; 5-10 minutes). Weekly coaching calls will last through the duration of the 8-week intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Control
Description: Participants in this group will receive weekly 15-minute videos (once weekly) focused on non-diet/non-fasting health educational content for 8 weeks. Participants will be asked to review the video at their convenience, prior to their weekly coaching call (5-10 minutes) with the study staff. Weekly topics will be as follows: Week 1: Sleep hygiene, Week 2: Sun safety, Week 3: Home safety, Week 4: Driving safety, Week 5: Hydration, Week 6: Dental health, Week 7: Working environment, Week 8: Communication.
Study: NCT04677166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy coupled with instillation
Description: Use of V.A.C. VeraFlo to treat skin grafts with NPWT coupled with instillation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Negative Pressure Wound Therapy
Description: standard negative pressure wound therapy via V.A.C. Ulta device at 125mmHg suction.
Study: NCT04894214

Intervention type: DIAGNOSTIC_TEST
Intervention: Arterial blood gas (ABG)
Description: Arterial blood gasses will be drawn during baseline PCV, and every 15 minutes during FCV and VCV respectively. pO2 (mmHg), pCO2 (mmHg) and pH will be recorded.

Intervention type: OTHER
Intervention: Recording of hemodynamic monitoring
Description: Hemodynamic parameters (invasive arterial blood pressure (mmHg) and heart rate (beats per minute)) will be recorded every 5 minutes.

Intervention type: OTHER
Intervention: Recording of respiratory monitoring
Description: Tidal volume (ml), respiratory rate (breaths per minute), minute volume (l/min), dynamic compliance (ml/cmH2O), resistance (cmH2O/l/min), plateau pressure (cmH2O), mean airway pressure (cmH2O), positive end-expiratory pressure (cmH2O), peak inspiratory pressure (cmH2O) and fraction of inspired oxygen will be recorded every 5 minutes.
Study: NCT04722848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib + Blinatumomab
Description: Patients aged 18-65 will receive Ponatinib at the dose of 45 mg/day for the first 22 days and then will reduce the dose to 30 mg (depending on the morphologic and molecular response), whereas patients older than 65 years will start Ponatinib at 30 mg/day, in order to avoid TAEs. Patients will continue treatment with Ponatinib up to day 70 (10 weeks of treatment), except for disease progression, intolerable toxicity, or withdrawal from study. Thereafter:~* Patients will receive Blinatumomab (minimum 2 cycles, up to a maximum of 5).~* Patients not achieving a CHR after 2 cycles of Blinatumomab will go off-study. After the 2 cycles of Blinatumomab patients aged 18-65 will be stratified for transplant allocation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy + Imatinib
Description: patients aged 18-65 will receive chemotherapeutic scheme combined with Imatinib. Elderly patients will receive Imatinib plus mild chemotherapy.
Study: NCT06589726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a single oral dose of placebo matched to enpatoran in either of treatment period 1, 2, 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive a single oral dose of moxifloxacin tablet (Treatment B) in either of treatment period 1, 2, 3 and 4.
Study: NCT04890613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-5461
Description: 150 mg sterile lyophilized powder containing 1% sucrose
Study: NCT06589726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive a single oral dose of moxifloxacin tablet (Treatment B) in either of treatment period 1, 2, 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive a single oral dose of moxifloxacin tablet (Treatment B) in either of treatment period 1, 2, 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Participants will receive a single oral dose of moxifloxacin tablet (Treatment B) in either of treatment period 1, 2, 3 and 4.
Study: NCT06589726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enpatoran low dose
Description: Participants will receive a single oral low dose of enpatoran tablet (Treatment C) in either of treatment period 1, 2, 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enpatoran low dose
Description: Participants will receive a single oral low dose of enpatoran tablet (Treatment C) in either of treatment period 1, 2, 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enpatoran low dose
Description: Participants will receive a single oral low dose of enpatoran tablet (Treatment C) in either of treatment period 1, 2, 3 and 4.
Study: NCT04890613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-5461
Description: 150 mg sterile lyophilized powder containing 1% sucrose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-5461
Description: 150 mg sterile lyophilized powder containing 1% sucrose
Study: NCT06589726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enpatoran low dose
Description: Participants will receive a single oral low dose of enpatoran tablet (Treatment C) in either of treatment period 1, 2, 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enpatoran high dose
Description: Participants will receive a single oral high dose of enpatoran tablet (Treatment D) in either of treatment period 1, 2, 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enpatoran high dose
Description: Participants will receive a single oral high dose of enpatoran tablet (Treatment D) in either of treatment period 1, 2, 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enpatoran high dose
Description: Participants will receive a single oral high dose of enpatoran tablet (Treatment D) in either of treatment period 1, 2, 3 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enpatoran high dose
Description: Participants will receive a single oral high dose of enpatoran tablet (Treatment D) in either of treatment period 1, 2, 3 and 4.
Study: NCT05035498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
Study: NCT05523492

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavioural Therapy
Description: All clients will receive the Culturally Enhanced Wellbeing Course. The Course was originally developed at Macquarie University in Australia and was then culturally enhanced by the Online Therapy Unit in Saskatchewan Canada. The course is a trans-diagnostic Internet-delivered cognitive behaviour therapy intervention targeting symptoms of depression and anxiety. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in order over 8 weeks. Therapists will spend \~15 mins. per week/per client offering support via emails and or phone calls.
Study: NCT04579861

Intervention type: OTHER
Intervention: Prospective data collection following gynaecological oncology surgery
Description: Prospective data collection and entry on database following gynaecological oncology surgery

Intervention type: OTHER
Intervention: Prospective data collection following gynaecological oncology surgery
Description: Prospective data collection and entry on database following gynaecological oncology surgery
Study: NCT06356740

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: blood test to assess :~* human leukocyte antigen (HLA)-B\*5701 status to identify risk of allergy or hypersensitivity to abacavir (the study treatment)~* IFN-signature ans IFN-alpha dosage~* human immunodeficiency virus (HIV), hepatitis B virus (HBV) and Hepatitis C virus (HCV) serologies~* Human chorionic gonadotropin (βHCG)~* HERVs dosage A biological collection will also be created. The total volume of blood collected specifically for the research for the entire duration of the study is 62.5 millilitre (mL) maximum.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: blood test to assess :~* human leukocyte antigen (HLA)-B\*5701 status to identify risk of allergy or hypersensitivity to abacavir (the study treatment)~* IFN-signature ans IFN-alpha dosage~* human immunodeficiency virus (HIV), hepatitis B virus (HBV) and Hepatitis C virus (HCV) serologies~* Human chorionic gonadotropin (βHCG)~* HERVs dosage A biological collection will also be created. The total volume of blood collected specifically for the research for the entire duration of the study is 62.5 millilitre (mL) maximum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment :Abacavir 600 mg/lamivudine 300 mg
Description: Patients randomised to the experimental arm will be required to take 1 tablet (600 mg lamivudine and 300 mg abacavir) once daily for 6 months in addition to their usual treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lupus Impact Tracker questionnaire
Description: Patients will be asked to complete the Lupus Impact Tracker questionnaire at visit V1 (randomisation visit), visit 3 (at 6 months of treatment) and visit 4 (12 months after visit 1).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lupus Impact Tracker questionnaire
Description: Patients will be asked to complete the Lupus Impact Tracker questionnaire at visit V1 (randomisation visit), visit 3 (at 6 months of treatment) and visit 4 (12 months after visit 1).
Study: NCT05056714

Intervention type: OTHER
Intervention: Questionaries
Description: The patient will answer several questionaries
Study: NCT06203431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET-26
Description: freeze-dried powder injection，The initial dose is 0.8 mg/kg, with an additional 50% starting dose if needed. single dose, Infusion time was 60s ± 5s.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate Injectable Emulsion
Description: lipid emulsion ，The initial dose is 0.3 mg/kg, with an additional 50% starting dose if needed.single dose, Infusion time was 60s ± 5s.
Study: NCT04987593

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Once a day daily intake of probiotics, at least for 28 consecutive days before giving birth and for at least 28 consecutive days after giving birth
Study: NCT06487949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan-amlodipine 80/5 mg FDC
Description: fix dose combination of valsartan 80 mg and Amlodipine 5 mg given as single pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan 80 mg and amlodipine 5 mg as free combination
Description: Free combination of valsartan 80 mg and amlodipine 5 mg given separately
Study: NCT05371704

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin Supplementation
Description: Participants will supplement daily with an over-the-counter oral multivitamin pill

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary Replication
Description: Patients will record their dietary intake in an estimated food diary during the first trial. During the second trial, participants will be asked to replicate their diet from the first trial

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Replication
Description: Patients will record their dietary intake in an estimated food diary during the first trial. During the second trial, participants will be asked to replicate their diet from the first trial